Wall Street analysts predict that Achaogen Inc (NASDAQ:AKAO) will announce earnings per share of ($0.96) for the current quarter, Zacks reports. Six analysts have provided estimates for Achaogen’s earnings, with the highest EPS estimate coming in at ($0.72) and the lowest estimate coming in at ($1.20). Achaogen posted earnings of ($0.85) per share during the same quarter last year, which would indicate a negative year over year growth rate of 12.9%. The company is expected to announce its next earnings results on Wednesday, November 14th.
On average, analysts expect that Achaogen will report full year earnings of ($3.93) per share for the current fiscal year, with EPS estimates ranging from ($4.20) to ($3.56). For the next financial year, analysts forecast that the firm will report earnings of ($2.38) per share, with EPS estimates ranging from ($3.22) to ($1.83). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Achaogen.
Achaogen (NASDAQ:AKAO) last issued its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The business had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million.
A number of equities research analysts have recently issued reports on AKAO shares. Cowen reissued a “buy” rating on shares of Achaogen in a research report on Friday, July 27th. Stifel Nicolaus upped their target price on shares of Achaogen from $14.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 7th. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Wedbush dropped their target price on shares of Achaogen from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, June 27th. Finally, BidaskClub downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Thursday, June 28th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $17.03.
Shares of AKAO stock traded down $0.02 during mid-day trading on Monday, reaching $3.98. 472,600 shares of the company’s stock traded hands, compared to its average volume of 1,131,724. Achaogen has a 12 month low of $3.31 and a 12 month high of $15.00. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.79 and a quick ratio of 3.79. The company has a market cap of $180.84 million, a price-to-earnings ratio of -1.26 and a beta of 0.71.
A number of institutional investors have recently modified their holdings of the stock. UBS Group AG raised its position in Achaogen by 681.5% during the first quarter. UBS Group AG now owns 297,632 shares of the biopharmaceutical company’s stock valued at $3,854,000 after purchasing an additional 259,546 shares in the last quarter. Bank of America Corp DE boosted its position in Achaogen by 274.7% during the 2nd quarter. Bank of America Corp DE now owns 198,204 shares of the biopharmaceutical company’s stock valued at $1,717,000 after acquiring an additional 145,305 shares in the last quarter. Granahan Investment Management Inc. MA bought a new stake in Achaogen during the 2nd quarter valued at approximately $1,220,000. Teton Advisors Inc. boosted its position in Achaogen by 324.2% during the 2nd quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock valued at $1,212,000 after acquiring an additional 107,000 shares in the last quarter. Finally, Wedbush Securities Inc. boosted its position in Achaogen by 266.7% during the 2nd quarter. Wedbush Securities Inc. now owns 91,850 shares of the biopharmaceutical company’s stock valued at $795,000 after acquiring an additional 66,800 shares in the last quarter. 60.46% of the stock is owned by institutional investors.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.